Thermo Fisher Scientific (TMO)

One-line summary: The cleanest US-listed beneficiary of the BIOSECURE-driven CDMO reshoring wave — a diversified life-sciences/bioproduction major whose contract-manufacturing network runs "effectively 100% in US and Western Europe," positioning it to capture the $10–20B/yr of contracts potentially relocating away from named Chinese CDMOs (WuXi AppTec/Biologics, BGI).

What it is

Thermo Fisher is a ~$200B+ diversified life-sciences company (lab equipment, reagents, diagnostics, and — the relevant segment here — pharma services / contract development & manufacturing (CDMO), including sterile fill-finish and bioproduction). Within this wiki it appears as the tradeable endpoint of the biosecure-act-domestic-cdmo-reshoring chain.

Valuation (August 27, 2026)

Last: $630.70 at the Thursday 27 Aug 2026 4:00 PM EDT close. From 2026-08-27-tmo-q2-2026-mix-vs-biosecure-wuxi-aug-2026 (stockanalysis).

Gage's judgment

Gage, 27 Aug 2026, via Leo. Not issuer grain. Range unchanged. Not a buy/sell/size. Not a paper sleeve.

• ~15% up / ~20% down over 18–24 months. Watch, not buy.
• Patheon 15.8% of sales, +5.5% (already on this page from the 10-Q).
• 10-Q/8-K unnamed BIOSECURE/WuXi. Legal path 1260H+OMB. Change conditions unmet.
• Pricing-power contradiction still open. OMB list 18 Dec is the next date that could move the call.

Why it matters to stock-market

BIOSECURE (signed into law Dec 2025, 5-yr transition through 2030) restricts federal-adjacent procurement from named Chinese biotech CDMOs. With ~79% of US biopharma companies holding a product or contract with a Chinese CDMO and WuXi's combined CDMO revenue ~$7B/yr, an estimated $10–20B/yr of contracts is potentially in play for relocation to Western CDMOs. Commercial-scale specialized capacity (GLP-1 peptide, AAV gene therapy) is concentrated — fewer than 15 CDMOs worldwide offer commercial-scale GLP-1 peptide manufacturing — and new build-to-FDA-approval takes 3–5 years, so the supply-demand gap is multi-year, giving qualified Western players pricing power. TMO is the one US-listed name explicitly flagged as a beneficiary. The removal of Catalent (taken private by Novo Holdings for $16.5B) tightens listed capacity further.

Key facts

• Q2 2026 mix (10-Q, period ended 2026-06-27). Pharma services (Patheon) $1.893 billion, about 15.8% of $11.994 billion company sales, up 5.5% reported. BioProduction $941 million (tools). LSS organic 3%. From 2026-08-27-tmo-q2-2026-mix-vs-biosecure-wuxi-aug-2026 (10-Q). Official 8-K Exhibit 99.1 is the earnings release for headline EPS/sales; this clip does not extract a separate EPS figure — do not invent one. Neither the 10-Q nor the 8-K Ex 99.1 names BIOSECURE or WuXi. From 2026-08-27-tmo-q2-2026-mix-vs-biosecure-wuxi-aug-2026.
• Named beneficiary — CEO on the record. From 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026 (citing BioProcess International): CEO Marc Casper called TMO "likely to be a long-term beneficiary" because its network operates "effectively 100% in US and Western Europe"; described as the fill/finish "market leader."
• Capex already flowing. TMO ~$2B US investment plus its acquisition of Sanofi's sterile fill-finish site — part of $24.86B disclosed CDMO investment in 2025, ~74% ($18.48B) to US facilities. From 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026 (PharmaSource).
• Scarcity kicker. Fewer than 15 CDMOs worldwide offer commercial-scale GLP-1 peptide manufacturing; commercial AAV gene-therapy capacity "similarly concentrated" → "strong pricing power, with sponsors often accepting higher costs for secure, timely supply." From 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026 (Alira Health).

Open questions

• How much of the CDMO/BIOSECURE tailwind is already in TMO's price? TMO is a $200B+ diversified name; fill-finish/bioproduction is one segment. Sizing that revenue share and its incremental margin is the key conviction question. From 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026.
• Danaher (DHR, via Cytiva bioprocessing consumables) is a plausible adjacent picks-and-shovels beneficiary but was NOT named in fetched sources — treat as speculative pending its own verification pass.

Sources

• 2026-08-27-tmo-q2-2026-mix-vs-biosecure-wuxi-aug-2026 — Q2 2026 10-Q mix (pharma services $1.893B / ~15.8% of $11.994B; BioProduction $941M; LSS organic 3%); 8-K Ex 99.1 unnamed BIOSECURE/WuXi; last $630.70 at Thu 27 Aug 2026 4:00 PM EDT (stockanalysis). Gage's judgment (via Leo, 27 Aug 2026) is on this page, not this source. Not a buy/sell/size. Encyclopedia not used.
• 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026

Related

• biosecure-act-domestic-cdmo-reshoring — the chain TMO is the tradeable endpoint of
• us-biotech-strategic-technology-offshoring — the parent forcing-function concept
• eli-lilly · novo-nordisk — GLP-1 demand is the largest pull on peptide CDMO capacity
• 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026